Risankizumab Achieves Primary Endpoints over Ustekinumab in SEQUENCE Trial

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Related Keywords

Laurent Peyrin Biroulet ,Roopal Thakkar ,Nancy University Hospital ,Image Analysis Group Laurent Peyrin Biroulet ,Infinity Institute ,Image Analysis Group ,United European Gastroenterology Week ,Nancy University ,Risankizumab ,Bustekinumab ,Clinical Remission ,Clinical Response ,Endoscopic Remission ,Endoscopic Response ,Cd ,Crohn Disease ,Crohn X27s Disease ,Ibd ,Inflammatory Bowel Disease ,Skyrizi ,Stelara ,